These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 28028823)
1. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint. Kunzmann K; Kieser M Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823 [TBL] [Abstract][Full Text] [Related]
2. Optimal adaptive two-stage designs for phase II cancer clinical trials. Englert S; Kieser M Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324 [TBL] [Abstract][Full Text] [Related]
3. Interval and point estimation in adaptive Phase II trials with binary endpoint. Nhacolo A; Brannath W Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157 [TBL] [Abstract][Full Text] [Related]
4. Optimal adaptive two-stage designs for early phase II clinical trials. Shan G; Wilding GE; Hutson AD; Gerstenberger S Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165 [TBL] [Abstract][Full Text] [Related]
5. Optimal and minimax three-stage designs for phase II oncology clinical trials. Chen K; Shan M Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337 [TBL] [Abstract][Full Text] [Related]
6. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials. Jin H; Wei Z Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088 [TBL] [Abstract][Full Text] [Related]
7. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints. Kunz CU; Kieser M Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719 [TBL] [Abstract][Full Text] [Related]
8. Minimax and admissible adaptive two-stage designs in phase II clinical trials. Shan G; Zhang H; Jiang T BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595 [TBL] [Abstract][Full Text] [Related]
9. Adaptive two-stage designs in phase II clinical trials. Banerjee A; Tsiatis AA Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547 [TBL] [Abstract][Full Text] [Related]
10. Adaptive designs for single-arm phase II trials in oncology. Englert S; Kieser M Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839 [TBL] [Abstract][Full Text] [Related]
11. Two-stage k-sample designs for the ordered alternative problem. Shan G; Hutson AD; Wilding GE Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050 [TBL] [Abstract][Full Text] [Related]
13. Performance of adaptive designs for single-armed phase II oncology trials. Kieser M; Englert S J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363 [TBL] [Abstract][Full Text] [Related]
14. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Zhou H; Lee JJ; Yuan Y Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563 [TBL] [Abstract][Full Text] [Related]
15. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs. Zhao J; Yu M; Feng XP BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655 [TBL] [Abstract][Full Text] [Related]
16. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials. Kim J; Schell MJ Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960 [TBL] [Abstract][Full Text] [Related]
17. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test. Shan G; Ma C; Hutson AD; Wilding GE J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517 [TBL] [Abstract][Full Text] [Related]
18. Optimal two-stage design of single arm Phase II clinical trials based on median event time test. Park Y PLoS One; 2021; 16(2):e0246448. PubMed ID: 33556130 [TBL] [Abstract][Full Text] [Related]
19. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family. Jiang W; Mahnken JD; He J; Mayo MS Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063 [TBL] [Abstract][Full Text] [Related]
20. Two-sample binary phase 2 trials with low type I error and low sample size. Litwin S; Basickes S; Ross EA Stat Med; 2017 Apr; 36(9):1383-1394. PubMed ID: 28118686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]